ASKC202

DRUG2 trials

Sponsors

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorEGFR Activating MutationMET PositiveNon-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

RecruitingNCT05306132

Jiangsu Aosaikang Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2022-08-08End: 2027-12-31Target: 150Updated: 2025-12-23

Phase 3

ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Not yet recruitingNCT07897188

Jiangsu Aosaikang Pharmaceutical Co., Ltd.EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive

Start: 2026-10-30End: 2032-11-20Target: 425Updated: 2026-10-27

Related Papers

Abstract CT118: Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors

Cancer Research2024-04-05